fluoxetine has been researched along with Lipidoses in 4 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 5.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| "The side effect profile and safety of fluoxetine are reviewed." | 3.75 | The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985) |
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| "Phospholipidosis is an adverse effect caused by numerous cationic amphiphilic drugs and can affect many cell types." | 1.36 | Predicting phospholipidosis using machine learning. ( Glen, RC; Lowe, R; Mitchell, JB, 2010) |
| " The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated." | 1.27 | Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lowe, R | 1 |
| Glen, RC | 1 |
| Mitchell, JB | 1 |
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Wernicke, JF | 1 |
| Zerbe, RL | 1 |
1 review available for fluoxetine and Lipidoses
| Article | Year |
|---|---|
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
1 trial available for fluoxetine and Lipidoses
| Article | Year |
|---|---|
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
3 other studies available for fluoxetine and Lipidoses
| Article | Year |
|---|---|
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Bio | 2010 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Safety of fluoxetine in the treatment of obesity.
Topics: Drug Interactions; Fluoxetine; Heart; Humans; Lipidoses; Liver; Obesity; Phospholipids; Propylamines | 1987 |